Patent · US Active

Liquid oral formulations for sildenafil

US11464778B2 · kind B2 · utility

2Cited by
0References
40Claims
0Family size

Assignee

Inventors

Key dates

Filing dateDec 24, 2018
Grant dateOct 11, 2022
Priority date
Expiry dateDec 24, 2038

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61K47/10
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present disclosure is directed to pharmaceutical compositions comprising a PDE V inhibitor and one or more pharmaceutical excipients or additives wherein the pharmaceutical compositions are in the form of liquid pharmaceutical compositions. The pharmaceutical compositions of the present disclosure are useful for the treatment of diseases or conditions which are treatable by administration of PDE V inhibitor drug such as pulmonary arterial hypertension, erectile dysfunction, etc.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.